Cyclosporin-based pharmaceutical compositions

Details Cyclosporin-based pharmaceutical compositions Cyclosporin-based pharmaceutical compositions

2005-12-27

2005-12-27

Tate, Christopher R. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S011400, C514S002600, C514S058000, C424S486000, C424S450000, C424S451000

Reexamination Certificate

active

06979672

ABSTRACT:
A pharmaceutical formulation for the oral administration of cyclosporin is described, which formulation is capable of providing substantially constant and foreseeable plasma levels of the active ingredient. The formulation has the following quali-quantitative composition by weight:(a) cyclosporin in the amount of from about 8 to about 12% of the total weight;(b) ethanol in the amount of from about 12 to about 18% of the total weight;(c) a polyoxyethylene/polyoxypropylene block copolymer in the amount of from about 8 to about 12% of the total weight;(d) water in the amount of from about 4 to about 6% of the total weight;(e) a solubilizer having an HLB from 13 to 15 in the amount of from about 28 to about 40% of the total weight;(f) an ester of a C1-C6alkyl alcohol and a C14-C18saturated fatty acid in the amount of from about 20 to about 30% of the total weight.

REFERENCES:
patent: 2865859 (1958-12-01), Lubowe
patent: 3678149 (1972-07-01), Prigal
patent: 4388307 (1983-06-01), Cavanak
patent: 4474761 (1984-10-01), Caen et al.
patent: 4612193 (1986-09-01), Gordon et al.
patent: 4649047 (1987-03-01), Kaswan
patent: 4659696 (1987-04-01), Hirai et al.
patent: 4670419 (1987-06-01), Uda et al.
patent: 4711902 (1987-12-01), Serno
patent: 4722914 (1988-02-01), Drye et al.
patent: 4839342 (1989-06-01), Kaswan
patent: 4990337 (1991-02-01), Kurihara et al.
patent: 5314685 (1994-05-01), Tyle et al.
patent: 5338761 (1994-08-01), Nakajima et al.
patent: 5342625 (1994-08-01), Hauer et al.
patent: 5589455 (1996-12-01), Woo
patent: 5733572 (1998-03-01), Unger et al.
patent: 5739105 (1998-04-01), Kim et al.
patent: 5756450 (1998-05-01), Hahn et al.
patent: 5773572 (1998-06-01), Fishleigh et al.
patent: 5977066 (1999-11-01), Cavanak
patent: 5980939 (1999-11-01), Kim et al.
patent: 6294192 (2001-09-01), Patel et al.
patent: 2002/0107183 (2002-08-01), Petszulat et al.
patent: 641 356 (1984-02-01), None
patent: 641 356 (1984-02-01), None
patent: 29 07 460 (1979-09-01), None
patent: 39 24 207 (1990-01-01), None
patent: 39 24 207 01 (1990-01-01), None
patent: 39 30 928 (1990-03-01), None
patent: 40 03 844 (1990-08-01), None
patent: 40 05 190 (1990-08-01), None
patent: 40 05 0190 (1990-08-01), None
patent: 0 094 157 (1983-11-01), None
patent: 0 143 305 (1985-06-01), None
patent: 0 170 623 (1986-02-01), None
patent: 0365044 (1990-04-01), None
patent: 0 327 280 (1992-03-01), None
patent: 0 697 881 (2002-12-01), None
patent: 2 642 650 (1990-03-01), None
patent: 2 015 339 (1979-09-01), None
patent: 2 228 198 (1990-08-01), None
patent: 2 230 440 (1990-10-01), None
patent: 94/23733 (1994-10-01), None
patent: WO 98/40051 (1998-09-01), None
patent: WO 01/12229 (2001-02-01), None
Smith, D., Microemulsions, pp. 299-314.
Sandimmune Product Information, Novartis, Mar. 2002.
Lutrol F 127 Technical Information, Polaxamer 407, Thickening agent and gel former for the pharmaceutical industry, BASF, Apr. 1999.
Oleochemicals -IMWITOR Fatty Acids Derivatives, online product information, Sasol, 2001.
Petszulat et al., publ. apl. no. US 202/0107183 A1 (Aug. 8, 2002).
Smith, D., Microemulsions, pp. 299-314.
Sandimmune Product Information, Novartis, Mar. 2002.
Lutrol F 127 Technical Information, Polaxamer 407, Thickening agent and gel former for the pharmaceutical industry, BASF, Apr. 1999.
Oleochemicals-Imwitor Fatty Acids Derivatives, online product information, Sasol, 2001.

Affiliated with

Also associated with

Rating

Cyclosporin-based pharmaceutical compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cyclosporin-based pharmaceutical compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclosporin-based pharmaceutical compositions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3465773